Bristol Myers Squibb has received the green light from the Food and Drug Administration for Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
“Sotyktu has the potential to become the new standard of care oral treatment for people with moderate-to-severe plaque psoriasis, given its profile in helping patients achieve clearer skin as demonstrated in the POETYK PSO clinical program,” said April Armstrong, clinical investigator in the POETYK PSO-1 trial and associate dean and professor of dermatology at the University of Southern California. “People living with moderate-to-severe plaque psoriasis face significant burdens, and Sotyktu is a welcome first-line systemic treatment option.”
Psoriasis is a widely prevalent, chronic, systemic immune-mediated disease that affects approximately 7.5 million people in the United States. Up to 90% of patients with psoriasis have plaque psoriasis, which is characterized by distinct, round or oval plaques typically covered by silvery white scales. Nearly one-quarter of people with psoriasis, or around 2 million in the United States, have cases that are considered moderate to severe.
“The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments. This is another extraordinary achievement for Bristol Myers Squibb, as we bring forward a new mechanism of action, the first oral treatment approved in nearly 10 years, and the first orally dosed once-daily treatment for moderate-to-severe plaque psoriasis,” said Samit Hirawat, chief medical officer at Bristol Myers Squibb. “We believe Sotyktu is a breakthrough in the treatment of patients with this condition, and we’re excited about its potential in other immune-mediated diseases.”
“Despite the availability of therapies, many people living with plaque psoriasis in the United States are untreated or undertreated,” said Leah Howard, president and CEO of the National Psoriasis Foundation. “The FDA approval of a new oral treatment is exciting news for the psoriasis community. We welcome this new treatment option.”
NCPA members meet with policymakers via Month of Action initiative
With midterm elections on the horizon, members of the National Community Pharmacists Association have completed dozens of pharmacy visits with policymakers or their staff as part of NCPA’s Month of Action initiative.
The Month of Action was in lieu of NCPA’s Congressional Pharmacy Fly-In to Washington, D.C., which typically takes place in April. By inviting policymakers to pharmacies instead, this initiative provided firsthand insight into the important role independent pharmacies play in their communities, the many ways that pharmacy teams help patients and the challenges facing the industry.
From Aug. 1 to Sept. 7, NCPA members across the country had plans for 60 visits in conjunction with NCPA’s Month of Action. Twenty-two of these were with legislators who serve in leadership roles in or on key committees for community pharmacy, including Sen. Ron Wyden (D-Ore.), chairman of the Senate Finance Committee, and Rep. Cathy McMorris Rodgers (R-Wash.), ranking member of the House Energy and Commerce Committee. Centers for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure visited a community pharmacy as well. Nearly 40% of pharmacies participating in the Month of Action hosted a legislator for the first time, an important step in building rapport with those making decisions central to the future of pharmacy.
“Forging a relationship with my senator and representative over the years has made them much more attuned to independent pharmacy issues,” said NCPA president Michele Belcher, owner of Grants Pass Pharmacy in Grants Pass, Ore.
Belcher has hosted several policymakers at her pharmacy and, in August, joined Wyden, Brooks-LaSure and others in visiting River Road Health Mart Pharmacy in Eugene.
“These opportunities show how decisions made in Washington affect independent pharmacies and patients across the country are times well spent,” she said. “I’m glad to have participated in NCPA’s Month of Action and am proud that so many independent pharmacists were prioritized by policymakers’ offices for meeting with this summer.”
One Brand is adding a bit of a crunch to its popular protein bars with a new product line — One Crunch.
Featuring 12 g of protein and 1 g of sugar, the bars come in peanut butter chocolate chip, cinnamon French toast and marshmallow treat varieties.
“After a day of working hard, new One Crunch protein bars are the perfect way to power through afternoon hunger and fatigue,” said Eric Clawson, One Brands’ general manager. “One Brands is known for our flavor innovation, and you can expect more exciting and delicious flavors like marshmallow or French toast, delivered without all the sugar and combined with powerful protein in this new line of bars.”
One Crunch bars are available for purchase online and in select stores at Walmart. The products will be launched at a later date on Amazon and Target.
General Mills sweetens snack time with Trix Popcorn
A new popcorn is joining the General Mills family.
Trix Popcorn is the latest launch from the company, which is a crunchy popcorn snack that contains a Trix-flavored fruity glaze along with bits of the cereal, the company said.
Inspired by other cereal and popcorn snack flavors that have been released, including Cinnamon Toast Crunch popcorn with Cinnadust Glaze and Cocoa Puffs popcorn with Cocoa Glaze, the snack features a balance of sweet and salty notes.
Consumers currently can find Trix Popcorn available at Sam’s Club in a 20-oz. bag that retails for $6.48 and in a 7-oz. bag that will retail for $3.69 at Walmart beginning in October.
Glamnetic takes on short round manicures with Choose Your Vibe collection
Glamnetic is showcasing a brand new press-on manicure collection designed for those who prefer a short round nail shape.
The Choose Your Vibe line features eight designs that include Lots of Love, Pretty Picnic, A Good Day, Shroomies, Pure Intentions, Day Trip, Mu Cherie and Hot Dot.
Like all of Glamnetic’s press on, each set in this new collection is reusable, customizable and made with high-quality material that is easy to file or clip and will not bend or split, the company said.
Made to last up to three weeks of wear, the nails are vegan, cruelty-free and topped with a layer of UV coating to achieve a salon-quality finish.
Each nail design retails for $14.99 each and the entire collection is available for $89.94 online.
Azurity Pharmaceuticals has been given the Food and Drug Administration’s green light for Konvomep (omeprazole and sodium bicarbonate for oral suspension) for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.
“We are very pleased that patients will soon have access to this FDA-approved oral liquid formulation option of a commonly prescribed proton pump inhibitor,” said Richard Blackburn, CEO of Azurity Pharmaceuticals. “Patients are our priority, and our purpose is to bring them new formulations that help them benefit from established medicines. Konvomep may give patients, particularly patients with difficulty swallowing pills or capsules, an option for treatment tailored to their needs.”
“Patients who struggle with taking solid oral dosage forms may be overlooked and have historically had limited FDA-approved treatment options available as liquid formulations,” said Olga Hilas, professor, clinical health professions at St. John’s University College of Pharmacy & Health Sciences.
It is expected that Konvomep will become commercially available in pharmacies nationwide in Q1 2023.